June 19, 2009 (Copenhagen, Denmark) — New recommendations for the diagnosis and management of systemic lupus erythematosus (SLE) with neuropsychiatric manifestations were presented here at EULAR 2009: ...

SLE is a heterogeneous disease, which can cause many different manifestations and symptoms, and traditionally did not have many treatment options. However, the picture is changing, and clinical ...

SLE is a complex and potentially life-threatening autoimmune disease. Part of the complexity stems from how it can differ from person to person – giving rise to marked heterogeneity in not only ...

Please provide your email address to receive an email when new articles are posted on . EULAR has released new recommendations for non-pharmacologic management of lupus and systemic sclerosis. The new ...

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem involvement. Systemic sclerosis (SSc) or scleroderma is another rheumatic autoimmune disease that ...

SLE is a heterogeneous disease, which can cause many different manifestations and symptoms, and traditionally did not have many treatment options. However, the picture is changing, and clinical ...

The European Alliance of Associations for Rheumatology (EULAR) has updated its recommendations for the management of systemic lupus erythematosus (SLE) based on emerging new evidence. For the 2023 ...

Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activity DZP showed consistent improvements in fatigue, ...

TORONTO, June 10, 2020 (GLOBE NEWSWIRE) -- Eli Lilly and Company presented new data for OLUMIANT® (baricitinib) at the virtual European Congress of Rheumatology (EULAR 2020). Highlights from OLUMIANT ...